Schizophrenia Research
Volume 91, Issue 1 , Pages 37-50 , March 2007

Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications

  • Robert K. McNamara

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0559, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 558 5601; fax: +1 513 558 2955.
    • ,
  • Ronald Jandacek

      Affiliations

    • Department of Pathology, University of Cincinnati, Cincinnati OH 45237, United States
    • ,
  • Therese Rider

      Affiliations

    • Department of Pathology, University of Cincinnati, Cincinnati OH 45237, United States
    • ,
  • Patrick Tso

      Affiliations

    • Department of Pathology, University of Cincinnati, Cincinnati OH 45237, United States
    • ,
  • Chang-Gyu Hahn

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States
    • ,
  • Neil M. Richtand

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0559, United States
    • Psychiatry Service, Department of Veterans Affairs Medical Center, Cincinnati, OH 45220, United States
    • ,
  • Kevin E. Stanford

      Affiliations

    • Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0559, United States

Received 14 September 2006 ,Revised 28 November 2006 ,Accepted 30 November 2006.

References 

  1. Ahmad A, Moriguchi T, Salem N. Decrease in neuron size in docosahexaenoic acid-deficient brain. Pediatr. Neurol. 2002;26:210–218
  2. Ahmad A, Murthy M, Greiner RS, Moriguchi T, Salem N. A decrease in cell size accompanies a loss of docosahexaenoate in the rat hippocampus. Nutr. Neurosci. 2002;5:103–113
  3. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry. 1999;156:1580–1589
  4. Albers M, Meurer H, Marki F, Klotz J. Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry. 1993;26(3):94–98
  5. Anderson GJ, Neuringer M, Lin DS, Connor WE. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr. Res. 2005;58(5):865–872
  6. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349(9067):1730–1734
  7. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003;62(3):195–204
  8. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry. 2003;53(1):56–64
  9. Basselin M, Chang L, Seemann R, Bell JM, Rapoport SI. Chronic lithium administration to rats selectively modifies 5-HT2A/2C receptor-mediated brain signaling via arachidonic acid. Neuropsychopharmacology. 2005;30:461–472
  10. Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology. 2005;30(6):1064–1075
  11. Bates C, Horrobin DF, Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr. Res. 1991;6(1):1–7
  12. Bechara A. The role of emotion in decision-making: evidence from neurological patients with orbitofrontal damage. Brain Cogn. 2004;55(1):30–40
  13. Bourre JM, Dumont OS, Piciotti MJ, Pascal GA, Durand GA. Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. Biochim. Biophys. Acta. 1992;1124:119–122
  14. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br. J. Nutr. 2002;88:411–420
  15. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J. Neurochem. 2004;90:979–988
  16. Carver JD, Benford VJ, Han B, Cantor AB. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 2001;56(2):79–85
  17. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 1988;78(5):587–591
  18. Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR, Chance GW. Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. Early Hum. Dev. 1980;4:121–129
  19. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J. Lipid Res. 1990;31(2):237–247
  20. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord. 2005;7:358–369
  21. Crespo-Facorro B, Kim J, Andreasen NC, O'Leary DS, Magnotta V. Regional frontal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study. Biol. Psychiatry. 2000;48(2):110–119
  22. DeMar JC, Ma K, Bell JM, Rapopo SI. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 2004;91:1125–1137
  23. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry. 2002;159(9):1596–1598
  24. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukot. Essent. Fat. Acids. 2003;69(6):393–399
  25. Garcia MC, Kim HY. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res. 1997;768(1–2):43–48
  26. Garey LJ, Von Bussmann KA, Hirsch SR. Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. Exp. Brain Res. 2006;173(2):234–242
  27. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 1990;28(6):495–501
  28. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr. Res. 1995;16(1):1–6
  29. Gershbein LL, Baburao K, Pedroso AF, Rao KC, Arellano G, Sumikoshi K. Regression analysis of total fatty acids from human whole brain according to age and sex. J. Appl. Biochem. 1985;7(1):55–63
  30. Giltay EJ, Gooren LJ, Toorians AW, Katan MB, Zock PL. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am. J. Clin. Nutr. 2004;80:1167–1174
  31. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry. 1997;54(7):660–669
  32. Goldstein JM, Goodman JM, Seidman LJ, Kennedy DN, Makris N, Lee H, et al. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch. Gen. Psychiatry. 1999;56(6):537–547
  33. Gur RE, Cowell PE, Latshaw A, Turetsky BI, Grossman RI, Arnold SE, et al. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch. Gen. Psychiatry. 2000;57(8):761–768
  34. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;(Suppl 2):17–54
  35. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry. 2003;53(5):431–441
  36. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 1991;30(8):795–805
  37. Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology. 2005;30(1):111–114
  38. Ichiki M, Kunugi H, Takei N, Murray RM, Baba H, Arai H, et al. Intra-uterine physical growth in schizophrenia: evidence confirming excess of premature birth. Psychol. Med. 2000;30:597–604
  39. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, et al. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J. Neurochem. 1998;70(2):763–771
  40. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for ‘hypofrontality’. Mol. Psychiatry. 1999;4(1):39–45
  41. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002;58(1):1–10
  42. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF Stanley Neuropathology Consortium. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol. Psychiatry. 2004;9(6):609–620
  43. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat. Rev., Neurosci. 2005;6(9):691–702
  44. Kringelbach ML, Rolls ET. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog. Neurobiol. 2004;72(5):341–372
  45. Kuehner C. Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr. Scand. 2003;108:163–174
  46. Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, Ozawa F, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry. 2003;60(9):878–888
  47. Landen M, Davidsson P, Gottfries CG, Mansson JE, Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr. Res. 2002;55(1–2):83–88
  48. Lasch J, Willhardt I, Kinder D, Sauer H, Smesny S. Fluorometric assays of phospholipase A2 activity with three different substrates in biological samples of patients with schizophrenia. Clin. Chem. Lab. Med. 2003;41(7):908–914
  49. Leng GC, Horrobin DF, Fowkes FG, Smith FB, Lowe GD, Donnan PT, et al. Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study. Arterioscler. Thromb. 1994;14(3):471–478
  50. Levant B, Crane JF, Carlson SE. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006;30(4):728–732
  51. Lin XH, Kitamura N, Hashimoto T, Shirakawa O, Maeda K. Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia. Biol. Psychiatry. 1999;46(12):1665–1671
  52. London ED, Ernst M, Grant S, Bonson K, Weinstein A. Orbitofrontal cortex and human drug abuse: functional imaging. Cereb. Cortex. 2000;10(3):334–342
  53. McCloughen A. The association between schizophrenia and cigarette smoking: a review of the literature and implications for mental health nursing practice. Int. J. Ment. Health Nurs. 2003;12(2):119–129
  54. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins, Leukot. Essent. Fat. Acids. 2006;74(4–5):329–349
  55. McNamara RK, Ostrander M, Abplanalp W, Richtand NM, Benoit S, Clegg D. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins, Leukot. Essent. Fat. Acids. 2006;74(4–5):237–257
  56. McNamara RK, Richtand NM, Levant B. Omega-3 fatty acid deficiency decreases dopamine D2 receptor binding and increases serotonin 5-HT2A receptor binding in the adult rat prefrontal cortex. Biol. Psychiatry. 2006;59:S146
  57. McNamara, R.K., Hahn, C-G., Jandacek, R., Rider, T., Tso, P., Stanford, K., Richtand, N.M., in press. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry (Electronic publication ahead of print).
  58. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 1997;54(12):1089–1095
  59. Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr. Res. 1995;18(1):85–86
  60. Metcalfe LD, Schmitz AA, Pelka JR. Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. Anal. Chem. 1966;38:514–515
  61. Myers CS, Contreras MA, Chang MC, Rapoport SI, Appel NM. Haloperidol downregulates phospholipase A(2) signaling in rat basal ganglia circuits. Brain Res. 2001;896(1–2):96–101
  62. Nilsson CL, Hellstrand M, Ekman A, Eriksson E. Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent. Br. J. Pharmacol. 1998;124(8):1651–1658
  63. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 1993;34(9):641–649
  64. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361(9354):281–288
  65. Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003;37(1):43–51
  66. Pawlosky RJ, Bacher J, Salem N. Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. Alcohol., Clin. Exp. Res. 2001;25:1758–1765
  67. Peet M. Nutrition and schizophrenia: an epidemiological and clinical perspective. Nutr. Health. 2003;17(3):211–219
  68. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001;49(3):243–251
  69. Peet M, Horrobin DF E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002;36(1):7–18
  70. Peterson BS, Vohr B, Staib LH, Cannistraci CJ, Dolberg A, Schneider KC, et al. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. JAMA. 2000;284:1939–1947
  71. Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature. 1991;353(6340):164–167
  72. Qu Y, Chang L, Klaff J, Balbo A, Rapoport SI. Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/−)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology. 2003;28(2):244–252
  73. Rao JS, Ertley RN, Demar JC, Rapoport SI, Bazinet RP, Lee HJ. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol. Psychiatry. 2006;(Electronic publication ahead of print)
  74. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004;30(4):901–911
  75. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry. 1997;54(5):487–494
  76. Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res. 1999;821(2):407–413
  77. Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, et al. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol. Psychiatry. 2005;57(4):399–405
  78. Suzuki H, Manabe S, Wada O, Crawford MA. Rapid incorporation of docosahexaenoic acid from dietary sources into brain microsomal, synaptosomal and mitochondrial membranes in adult mice. Int. J. Vitam. Nutr. Res. 1997;67(4):272–278
  79. Tisserand DJ, Pruessner JC, Sanz Arigita EJ, van Boxtel MP, Evans AC, Jolles J, et al. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. NeuroImage. 2002;17:657–669
  80. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain collection and neuropathology consortium. Schizophr. Res. 2000;44(2):151–155
  81. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knab MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry. 2005;57(3):252–260
  82. Trzeciak HI, Kalacinski W, Malecki A, Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur. Arch. Psychiatry Clin. Neurosci. 1995;245(3):179–182
  83. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000;42(1):7–17

PII: S0920-9964(06)00503-2

doi: 10.1016/j.schres.2006.11.027

Schizophrenia Research
Volume 91, Issue 1 , Pages 37-50 , March 2007

Article Tools

* Image Usage & Resolution